Approved
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen
FDA Clears BioNTech-MediLink ADC Trial to Resume with Reduced Doses
BioNTech, MediLink, ADC trial, FDA approval, lower doses, cancer treatment, HER3, patient safety
FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery
FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC
FDA Approval of Amgen’s Imdelltra for Lung Cancer Amidst Challenges and Market Competition
Amgen, Imdelltra, FDA approval, lung cancer, bispecific T-cell engager, adverse events, Merck, Curon, Legend Biotech
Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma
Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.
Incyte and Syndax Secure FDA Approval for Niktimvo, a Breakthrough Treatment for Chronic Graft-Versus-Host Disease
Incyte, Syndax, Niktimvo, FDA approval, graft-versus-host disease, GVHD, axatilimab-csfr, chronic GVHD, allogeneic stem cell transplant
Novo Nordisk’s Wegovy Approved in China: Implications and Future Challenges
Novo Nordisk, Wegovy, semaglutide, obesity treatment, China approval, generic competition, patent expiration, pharmaceutical market
Gilead’s $4.3B Acquisition of CymaBay Yields FDA Approval for Autoimmune Liver Disease Treatment
Gilead Sciences, CymaBay, FDA Approval, Autoimmune Liver Disease, Seladelpar, Primary Biliary Cholangitis
AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment
AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient
Galderma’s IL-31 Blocker Nemluvio Gains FDA Approval for Prurigo Nodularis
Galderma, Nemluvio, IL-31 blocker, FDA approval, prurigo nodularis, therapeutic dermatology